Cargando…

P-007: HYDROXYUREA FOR THE MANAGEMENT OF SICKLE CELL DISEASE IN LOW- AND MIDDLE-INCOME COUNTRIES: A SYSTEMATIC REVIEW (2000–2022)

Detalles Bibliográficos
Autores principales:	L., TSHILOLO, K., MARFO, F., ADISON, S., KHAN, V., PAINTSIL
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Poster Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426789/ http://dx.doi.org/10.1097/01.HS9.0000872932.23177.e8

Ejemplares similares

P1489: MANAGEMENT OF SICKLE CELL DISEASE WITH HYDROXYUREA: A SYSTEMATIC REVIEW FROM LOW- AND MIDDLE-INCOME COUNTRIES
por: Paintsil, V., et al.
Publicado: (2022)

P-009: IDENTIFYING BARRIERS FOR PATIENTS WITH SICKLE CELL DISEASE TO ACCESS TREATMENT WITH HYDROXYUREA – A QUALITATIVE ANALYSIS OF THE SUPPLY CHAIN IN GHANA
por: S., GRAVEN, et al.
Publicado: (2022)

Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries
por: Mulaku, Mercy, et al.
Publicado: (2013)

P138: WHITE PAPER: ASSESSMENT OF INTERNATIONAL SICKLE CELL DISEASE GUIDELINES IN HIGH-, MIDDLE-, AND LOW-INCOME COUNTRIES
por: Suthar, N, et al.
Publicado: (2022)

P-034: EFFECTS OF HYDROXYUREA ON SKELETAL MUSCLE MICROVASCULATURE OF MICE WITH SICKLE CELL DISEASE
por: M., RICCETTI, et al.
Publicado: (2022)

P-048: INFLUENCE OF SEVEN GENETIC POLYMORPHISMS ON THE RESPONSE TO SICKLE CELL DISEASE THERAPY WITH HYDROXYUREA
por: O., FRANCO SANTOS, et al.
Publicado: (2022)

O-01: HYDROXYUREA REDUCES THE TRANSFUSION BURDEN IN CHILDREN WITH SICKLE CELL ANEMIA IN SUB-SAHARAN AFRICA: THE REACH EXPERIENCE
por: A., POWER-HAYS, et al.
Publicado: (2022)

P-090: IS A DEDICATED MARKETING APPROVAL OF HYDROXYUREA IN SICKLE CELL DISEASE MAY INCREASE THE CLINICAL BENEFIT OF THE DRUG?
por: F., GALACTÉROS, et al.
Publicado: (2022)

P102: PLASMA FREE HEMOGLOBIN AND REACTIVE OXYGEN SPECIES IN SICKLE CELL ANAEMIA PATIENTS UNDER HYDROXYUREA AND GLUTAMINE THERAPY
por: Giannaki, A, et al.
Publicado: (2022)

Sequence and annotation of the Wizard007 mycobacterium phage genome
por: Anyanwu, Ejike, et al.
Publicado: (2010)

P-028: CIRCULATING CD34+CD235A+ CELL COUNT CORRELATES WITH LEVELS OF HBF IN SICKLE CELL ANEMIA PATIENTS UNDER HYDROXYUREA TREATMENT
por: J., MILHOMENS, et al.
Publicado: (2022)

P-017: POINT-OF-CARE DIAGNOSTIC FOR QUANTIFICATION OF FOETAL HAEMOGLOBIN (HB F) LEVELS IN MONITORING HYDROXYUREA THERAPY FOR CHILDREN WITH SICKLE CELL DISEASE (SCD) IN GHANA
por: C., SEGBEFIA, et al.
Publicado: (2022)

P1425: SYSTEMATIC INVESTIGATION OF HYDROXYUREA TREATMENT EFFECT IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE
por: Bhat, Varsha, et al.
Publicado: (2023)

P-042: POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS ANALYSIS OF HYDROXYUREA, IN ADULT PATIENTS WITH SICKLE CELL DISEASE (SCD) RECEIVING BOTH TABLETS OR CAPSULES FORMULATIONS, AND EVALUATION OF DISEASE MARKERS
por: P., BARTOLUCCI, et al.
Publicado: (2022)

P-039: ALTERNATIVE DOSING AND PREVENTION OF TRANSFUSIONS (ADAPT): A PROSPECTIVE TRIAL EVALUATING TRANSFUSION UTILIZATION AND THE FEASIBILITY OF PHARMACOKINETIC HYDROXYUREA DOSING IN CHILDREN WITH SICKLE CELL ANEMIA IN UGANDA
por: POWER-HAYS, A., et al.
Publicado: (2022)

Mapping inequalities in exclusive breastfeeding in low- and middle-income countries, 2000–2018
por: Bhattacharjee, Natalia V., et al.
Publicado: (2021)

P-075: HYDROXYUREA: EFFECTS ON TREATMENT OF CHILDREN WITH HEMOGLOBINOPATHY SC
por: A., CAMPOS, et al.
Publicado: (2022)

P-018: MILESTONES ALONG MY PERSONAL JOURNEY WITH HYDROXYUREA
por: A., SHAKIR
Publicado: (2022)

S129: IMPLEMENTATION OF HYDROXYUREA THERAPY FOR SICKLE CELL DISEASE ON A LARGE SCALE IN GHANA
por: Ohene-Frempong, K, et al.
Publicado: (2022)

PI-03: THE EFFECT OF HYDROXYUREA IN THE GUT MICROBIOME OF ANGOLAN CHILDREN WITH SICKLE CELL DISEASE
por: M., DELGADINHO, et al.
Publicado: (2022)

5595849 THE GUT MICROBIOME AND HYDROXYUREA EFFECT ON SICKLE CELL DISEASE CHILDREN FROM ANGOLA
por: Brito, M., et al.
Publicado: (2023)

Access to cardiovascular medicines in low- and middle-income countries: a mini review
por: Harrison, Mark Amankwa, et al.
Publicado: (2023)

Hydroxyurea Treatment for Sickle Cell Disease
por: Steinberg, Martin H.
Publicado: (2002)

P007: Risk factors for mortality among non-icu patients with catheter-related bacteraemia
por: Hornero, A, et al.
Publicado: (2013)

P007 Eating in alignment with the circadian clock: A strategy to reduce the metabolic impact of nightwork
por: Centofanti, S, et al.
Publicado: (2021)

Trends and outcomes in primary health care expenditures in low-income and middle-income countries, 2000–2017
por: Schneider, Matthew T, et al.
Publicado: (2021)

Assessing new strategies for TB diagnosis in low- and middle-income countries
por: Kritski, Afranio Lineu, et al.
Publicado: (2014)

P007. Inhibition of monoacylglycerol lipase activity modulates the activation of brain structures relevant for migraine pathogenesis
por: Greco, Rosaria, et al.
Publicado: (2015)

Access to iodized salt in 11 low- and lower-middle-income countries: 2000 and 2010
por: Tran, Thach Duc, et al.
Publicado: (2016)

Hydroxyurea Therapy for Children With Sickle Cell Anemia in Sub‐Saharan Africa: Rationale and Design of the REACH Trial
por: McGann, Patrick T., et al.
Publicado: (2015)

Parafoveal acute middle maculopathy (PAMM) in sickle cell disease after discontinuation of hydroxyurea
por: Parikh, Pooja, et al.
Publicado: (2022)

5613177 AN INTERNATIONAL, LONGITUDINAL, OBSERVATIONAL STUDY TO EVALUATE THE PSYCHOMETRIC PROPERTIES OF A DAILY DIARY FOR ADOLESCENTS AND ADULTS WITH SICKLE CELL DISEASE
por: Rizio, A.R., et al.
Publicado: (2023)

Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000–17
Publicado: (2020)

An integrated hospital-district evaluation for communicable diseases in low/middle-income countries
por: Tavoschi, L, et al.
Publicado: (2022)

P1446: HYDROXYUREA AND LIMB ULCERS: IS IT WORTH SUSPENDING? RETROSPECTIVE COHORT STUDY OF BRAZILIAN ADULT PATIENTS WITH SICKLE CELL DISEASE
por: Benites, Bruno, et al.
Publicado: (2023)

P-003: EVALUATION OF TREATMENT PATTERN, HEALTHCARE RESOURCE UTILIZATION AND COSTS OF ILLNESS FOR SICKLE CELL DISEASE IN GHANA: A PRIVATE MEDICAL INSURANCE CLAIMS DATABASE STUDY
por: Y., DEI-ADOMAKOH, et al.
Publicado: (2022)

Impact of chest pain protocol in the use of fibrinolytic therapy in a private hospital network with access to telemedicine in a middle income country
por: MB Silva, Pedro Gabriel, et al.
Publicado: (2015)

The Context Assessment for Community Health tool - investigating why what works where in low- and middle-income settings
por: Bergström, Anna, et al.
Publicado: (2014)

Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018
por: Kinyoki, Damaris, et al.
Publicado: (2021)

Mapping geographical inequalities in access to drinking water and sanitation facilities in low-income and middle-income countries, 2000–17
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bgsm2gl0rj2v89co2asj0leghv